

NEW ZEALAND DATA SHEET

1 Paracetamol Kabi Solution for Infusion 10mg/mL

2 QUALITATIVE AND QUANTITATIVE COMPOSITION

Paracetamol Kabi solution for infusion contains 10 mg/mL of paracetamol (50 mL vial/bag contains 500 mg of paracetamol, 100 mL vial/bag contains 1 g of paracetamol).

Paracetamol Kabi solution for infusion contains the excipients mannitol, cysteine hydrochloride, nitrogen (as protective gas), water for injections.

3 PHARMACEUTICAL FORM

Paracetamol solution for infusion 10 mg/mL is a clear to slightly yellowish solution.

Paracetamol is a white crystalline solid or powder chemically described as 4 – acetamidophenol. It is soluble in water (1 in 70), soluble in alcohol (1 in 7), acetone (1 in 13), glycerol (1 in 40), propylene glycol (1 in 9) and also soluble in solutions of the alkali hydroxides.

4 CLINICAL PARTICULARS

4.1 Therapeutic indications

Paracetamol 10 mg/mL solution for infusion is indicated for the relief of mild to moderate pain and the reduction of fever where an intravenous route of administration is considered clinically necessary.

4.2 Dose and method of administration

The prescribed dose must be based on the patient's weight.

Unintentional overdose can lead to serious liver damage and death (see section 4.9 OVERDOSE).

Healthcare providers are reminded that it is essential to follow both the weight-related dose recommendations and to consider individual patient risk factors for hepatotoxicity including hepatocellular insufficiency, chronic alcoholism, chronic malnutrition (low reserves of hepatic glutathione), and dehydration (see section 4.2 DOSE AND METHOD OF ADMINISTRATION – Hepatic Impairment).

It is recommended that suitable oral analgesic treatment be substituted for Paracetamol solution for infusion as soon as the patient can be treated by the oral route (see section 4.3 CONTRAINDICATIONS).

Intravenous Route

Paracetamol solution for infusion 10 mg/mL should not be mixed with other medicinal products. Use of the 100 mL vial/bag is restricted to adults, adolescents and children weighing more than 33 kg.

Dosage

Dosing is based on patient weight. Dosing recommendations are presented in the table below:

Patient Weight	Paracetamol dose (10mg/mL) per administration	Minimum interval between each administration	Maximum daily dose [#]
> 50 kg	1 g (i.e. one 100 mL vial) Up to 4 times per day	4 hours*	≤ 4 g Must not exceed 4 g in 24 hours

> 33 kg and ≤ 50 kg	15 mg/kg (i.e. 1.5 mL solution per kg) Up to 4 times per day	4 hours*	≤ 60 mg/kg, without exceeding 3 g Must not exceed 3 g in 24 hours
> 10 kg and ≤ 33 kg	15 mg/kg (i.e. 1.5 mL solution per kg) Up to 4 times per day	6 hours	≤ 60 mg/kg, without exceeding 2 g Must not exceed 2 g in 24 hours
≤ 10 kg **	7.5 mg/kg (i.e. 0.75 mL solution per kg) The volume must not exceed 7.5 mL per dose) Up to 4 times per day.	6 hours	≤ 30 mg/kg Must not exceed 30 mg/kg in 24 hours

*The minimum interval between each administration must be 4 hours in patients without hepatic or renal impairment. However, in patients with renal and/or hepatic impairment the minimum interval between doses must not be less than 6 hours. # The maximum daily dose takes into account all medicines containing paracetamol or propacetamol ** No safety and efficacy data are available for premature neonates. There is limited data on the use of paracetamol 10mg/mL solution for infusion in neonates and infants <6 months of age (see section 5.2 PHARMACOKINETIC PROPERTIES).

Hepatic Impairment

In patients with impaired hepatic function, the dose must be reduced or the dosing interval prolonged. The maximum daily dose should not exceed 60 mg/kg/day (not exceeding 2 g/day) in the following situations:

- Adults weighing less than 50 kg
- Chronic or compensated active hepatic disease, especially those with mild to moderate hepatocellular insufficiency
- Gilbert's syndrome (familial hyperbilirubinaemia)
- Chronic alcoholism
- Chronic malnutrition (low reserves of hepatic glutathione)
- Dehydration

Method of administration

The paracetamol solution is administered as a 15-minute intravenous infusion; it contains no antimicrobial agent, and is for single use in one patient only.

Compatibility

Paracetamol Kabi 10 mg/mL solution for infusion can also be diluted in a 0.9% sodium chloride or 5% glucose solution up to one tenth. In this case, use the diluted solution within the hour following its preparation (infusion time included).

Instructions for use/handling

Before administration, the product should be visually inspected for any particulate matter and discolouration.

As for all solutions for infusion presented in glass vials, it should be remembered that close monitoring is needed notably at the end of the infusion, regardless of the administration route. This monitoring at the end of the perfusion applies particularly for central route infusion, in order to avoid air embolism.

It is recommended that for the administration of paracetamol solution for infusion 10 mg/mL, a syringe or giving set with a diameter equal to or below 0.8mm should be used for solution sampling. In addition, it is recommended that the bung is pierced at the location designed for needle introduction (where the thickness of the bung is the lowest). If these recommendations are not adhered to the likelihood of bung fragmentation or the bung being forced into the vial is increased.

Paediatric Patients

Paracetamol Kabi should not be hung as an infusion due to the small volume of the product to be administered in the paediatric population.

To avoid dosing errors in neonates and infants (≤ 10 kg) and confusion between milligrams (mg) and millilitres (mL), it is recommended to specify the intended volume for administration in millilitres (mL). The volume of Paracetamol Kabi (10 mg/mL) administered should never exceed 7.5 mL per dose in this weight group. In neonates and infants (≤ 10 kg), very small volumes will be required. A 5 mL or 10 mL syringe should be used to measure the dose as appropriate for the weight of the child and the desired volume.

For paediatric dosing, the 50 mL vial/bag of Paracetamol Kabi can be diluted using either a 0.9% sodium chloride solution or a 5% glucose solution up to one-tenth dilution (one volume paracetamol injection into nine volumes diluent). The diluted solution must be used within one hour following its preparation (infusion time included).

4.3 Contraindications

Paracetamol 10mg/mL solution for infusion is contraindicated:

- In cases of hypersensitivity to paracetamol or to propacetamol hydrochloride (prodrug of paracetamol) or to any of the excipients
- In cases of severe hepatocellular insufficiency
- In patients with hepatic failure or decompensated active liver disease.

It is recommended to use a suitable analgesic oral treatment as soon as this administration route is possible.

In order to avoid the risk of overdose; check that other medicines administered do not contain paracetamol.

Doses higher than the recommended entail a risk of very serious liver damage. Clinical symptoms and signs of liver damage are usually seen first after two days with a maximum usually after 4 to 6 days. Treatment with antidote should be given as soon as possible (see section 4.2 DOSE AND METHOD OF ADMINISTRATION).

4.4 Special warnings and precautions for use

Paracetamol solution for infusion should be used with caution in cases of:

- Hepatocellular insufficiency, including Gilbert's syndrome (familial hyperbilirubinaemia)
- Severe renal insufficiency (creatinine clearance ≤ 30 mL/min)
- Glucose 6 Phosphate Dehydrogenase (G6PD) deficiency (may lead to haemolytic anaemia)
- Chronic alcoholism, excessive alcohol intake (3 or more alcoholic drinks every day).
- Anorexia, bulimia or cachexia; chronic malnutrition (low reserves of hepatic glutathione)
- Dehydration, hypovolaemia.

(see sections 4.2 DOSE AND METHOD OF ADMINISTRATION and 5.2 PHARMACOKINETIC PROPERTIES)

The total dose of paracetamol should not exceed 4 g per day for patients weighing 50 kg or more, 60 mg/kg for patients weighing 50 kg or less and more than 33 kg (without exceeding 3 g), 60 mg/kg for patients weighing 33 kg or less and more than 10 kg (without exceeding 2 g) and 30 mg/kg for patients

weighing 10 kg or less. It is important to consider the contribution of all paracetamol containing medications, including non-prescription, oral or PR forms of the drug to this total daily paracetamol dose prior to administering Paracetamol solution for infusion. If the daily dose of paracetamol from all sources exceeds the maximum, severe hepatic injury may occur (See section 4.2 OVERDOSE).

Paracetamol can cause serious skin reactions such as acute generalised exanthematous pustulosis (AGEP), Stevens-Johnson syndrome (SJS), and toxic epidermal necrolysis (TEN), which can be fatal. Patients should be informed about the signs of serious skin reactions, and use of the drug should be discontinued at the first appearance of skin rash or any other sign of hypersensitivity. High Anion Gap Metabolic Acidosis

Cases of high anion gap metabolic acidosis (HAGMA) due to pyroglutamic acidosis have been reported in patients with severe illness such as severe renal impairment and sepsis, or patients with malnutrition and other sources of glutathione deficiency (e.g. chronic alcoholism) who were treated with paracetamol at therapeutic dose for a prolonged period or a combination of paracetamol and flucloxacillin. If HAGMA due to pyroglutamic acidosis is suspected, prompt discontinuation of paracetamol and close monitoring is recommended. The measurement of urinary 5-oxoproline may be useful to identify pyroglutamic acidosis as underlying cause of HAGMA in patients with multiple risk factors.

Hepatic impairment

Patients with hepatic insufficiency, chronic alcoholism, chronic malnutrition or dehydration may be at a higher risk of liver damage following administration of Paracetamol solution for infusion.

Paracetamol solution for infusion should be used with caution in cases of hepatocellular insufficiency, including Gilbert's syndrome (familial hyperbilirubinaemia).

See section **4.3 Contraindications**.

Use in renal impairment

Paracetamol solution for infusion should be used with caution in cases of severe renal insufficiency (creatinine clearance ≤ 30 mL/min).

Paediatric population

There is limited data on the use of paracetamol solution for infusion in neonates and infants <6 months of age (see sections 5.2 Pharmacokinetic Properties and 4.2 Dose and Method of Administration.)

4.5 Interaction with other medicines and other forms of interaction

Probenecid causes an almost 2-fold reduction in clearance of paracetamol by inhibiting its conjugation with glucuronic acid. A reduction of the paracetamol dose should be considered for concomitant treatment with probenecid.

Caution should be paid to the concomitant intake of enzyme-inducing agents. These substances include but are not limited to: barbiturates, isoniazid, anticoagulants, zidovudine, amoxicillin + clavulanic acid, carbamazepine and ethanol. Induction of metabolism of paracetamol from enzyme inducers may result in an increased level of hepatotoxic metabolites.

Concomitant use of paracetamol (4 g per day for at least 4 days) with oral anticoagulants may lead to slight variations of INR values. In this case, increased monitoring of INR values should be conducted during the period of concomitant use as well as for one week after paracetamol treatment has been discontinued.

Phenytoin administered concomitantly may result in decreased paracetamol effectiveness and an increased risk of hepatotoxicity. Patients receiving phenytoin therapy should avoid large and/or chronic doses of paracetamol. Patients should be monitored for evidence of hepatotoxicity.

Busulfan – busulfan is eliminated from the body via conjugation with glutathione. Concomitant use with paracetamol may result in reduced busulfan clearance.

Diflunisal – concomitant diflunisal increases paracetamol plasma concentrations and this may increase hepatotoxicity.

Caution should be taken when paracetamol is used concomitantly with flucloxacillin as concurrent intake has been associated with high anion gap metabolic acidosis due to pyroglutamic acidosis, especially in patients with risk factors. (see section 4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE)

4.6 Fertility, pregnancy and lactation

Pregnancy

Paracetamol has been taken by a large number of pregnant women and women of childbearing age without any proven increase in the frequency of malformations or other direct or indirect harmful effects on the foetus having been observed.

The reproductive toxicity of IV paracetamol has not been directly tested in animal studies. IV administration of maternotoxic doses of the pro-drug, propacetamol, to pregnant rats and rabbits during organogenesis increased the incidence of extraneous ribs and sacral vertebrae (normal 2 variations in these species) at 0.7-fold (rabbits; mg/m² basis) and 7-fold (rats; AUC basis) the maximum anticipated clinical exposure to paracetamol. The clinical significance of these findings is not known. No signs of pre/post-natal toxicity were observed in rats treated with IV propacetamol at maternal exposures (based on AUC) greater than 3-fold those anticipated at the maximum clinical dose.

Nevertheless, Paracetamol solution for infusion should only be used during pregnancy after a careful benefit-risk assessment. In pregnant patients, the recommended posology and duration must be strictly observed.

Breast Feeding

After oral administration, paracetamol is excreted into breast milk in small quantities. Rash in nursing infants has been reported. No signs of toxicity were observed in rat pups of dams that received IV propacetamol postpartum at maternal exposures (based on AUC) greater than twice those anticipated at the maximum clinical dose. Paracetamol solution for infusion may be used in breast-feeding women, but caution should be observed.

Fertility

IV paracetamol (administered as propacetamol) had no effect on fertility of rats at systemic exposure levels (based on AUC) greater than twice those anticipated at the maximum clinical dose.

4.7 Effects on ability to drive and use machines

Not relevant.

4.8 Undesirable effects

The overall incidence of adverse events in patients treated with IV paracetamol compared to placebo within the clinical trial set can be observed in the tables below.

Adverse Events in Adults - greater than 1% (observed in the clinical trial set)

	IV Paracetamol % n= 99	Placebo% n= 102
Neurological		
Dizziness	2.7	2.9
Headache	1.3	4.9
Dystonia	-	-
Gastrointestinal		
Vomiting	4.0	2.9
Dry mouth	-	-
Diarrhoea	1.3	-
Constipation	6.7	11.8
Nausea	10.0	8.8
Dyspepsia	1.3	-
Enlarged abdomen	2.0	-
Gastrointestinal disorder NOS	2.0	-
Haematological		
Anaemia	2.7	6.9
Post operative haemorrhage	2.0	-
Hepatobiliary		
Gamma GT – increase	1.3	-
SGPT – increase	1.3	-
Psychiatric		
Insomnia	-	1.96
Skin and Appendage		
Injection site pain	2.0	-
Injection site reaction	2.67	-
Post-operative site reaction	2.67	-
Pruritus	3.3	4.9
Respiratory		
Alveolitis	1.3	2.94
Coughing	2.0	-
Endocrine/Metabolic		
Hyperglycaemia	1.3	-
Hypokalaemia	1.3	-
General		
Fatigue	1.59	-
Fever	-	5.9
Oedema – peripheral	-	-
Chest pain	1.33	-

Adverse Events in Children - greater than 1% (observed in the clinical trial set)

	IV Paracetamol % n = 95
Skin and Appendage	
Injection site pain	14.74
Injection site reaction	-
Neurological	
Hypotonia	1.05
Gastrointestinal	
Nausea	1.05
Vomiting	5.26
Abdominal pain	-
Eructation	-
Body as A Whole	
Fever	1.05

As with all paracetamol products, adverse drug reactions are rare ($>1/10000$, $<1/1000$) or very rare ($<1/10000$), they are described below:

Organ / System	Rare $>1/10000$, $<1/1000$	Very Rare $<1/10000$	Isolated Reports
General disorders and administration site condition	- Malaise	- Hypersensitivity reaction	
Cardiac disorders	- Hypotension	- Shock	
Hepatobiliary disorders	- Increased levels of hepatic transaminases		
Blood and the lymphatic system disorders	- Agranulocytosis neutropaenia		- Thrombocytopaenia
Neurological		- Neurological disorders	- Coma
Renal/Genitourinary		-Acute renal failure	
Skin and subcutaneous tissue disorders	- Macular rash - Injection site reaction	- Maculo-papular rash - Pemphigoid reaction - Pustular rash	- Lyell syndrome

Post Market Adverse Events for Propacetamol/Paracetamol

The following adverse events have also been reported during post-marketing surveillance, but incidence rate (frequency) is not known.

Organ System	Adverse Event
Blood and the lymphatic system disorders	- Thrombocytopaenia
Cardiac disorders	- Tachycardia
Gastrointestinal disorders	- Nausea - Vomiting
General disorders and administration site conditions	- Administration site reaction
Hepatobiliary disorders	- Fulminant hepatitis - Hepatic necrosis - Hepatic failure - Hepatic enzymes increased
Immune system disorders	- Angioneurotic (Quincke's) oedema - Anaphylactic shock - Anaphylaxis - Hypersensitivity reactions (ranging from simple rash or urticaria to anaphylactic shock) have been reported and require the discontinuation of treatment
Skin and subcutaneous tissue disorders	- Erythema - Flushing - Pruritus - Rash - Urticaria - Acute generalised exanthematous pustulosis (AGEP) - Toxic epidermal necrolysis (TEN) - Steven-Johnson syndrome (SJS)

High anion gap metabolic acidosis with frequency "Not known" (cannot be estimated from the available data): Cases of high anion gap metabolic acidosis due to pyroglutamic acidosis have been observed in patients with risk factors using paracetamol (see section 4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE). Pyroglutamic acidosis may occur as a consequence of low glutathione levels in these patients.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicine is important. It allows continued monitoring of the benefit/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions <https://nzphvc.otago.ac.nz/reporting/>

4.9 Overdose

There is a risk of poisoning, particularly in elderly subjects, in young children, in patients with liver disease, in cases of chronic alcoholism, in patients with chronic malnutrition and in patients receiving enzyme inducers. Poisoning may be fatal in these cases. Acute overdose with paracetamol may also lead to acute renal tubular necrosis.

Symptoms generally appear within the first 24 hours and comprise of nausea, vomiting, anorexia, pallor and abdominal pain. Overdose, 7.5 g or more of paracetamol in a single administration in adults or 140 mg/kg of body weight in a single administration in children, causes cytolytic hepatitis likely to induce complete and irreversible hepatic necrosis, resulting in acute or fulminant hepatic failure, hepatocellular insufficiency, metabolic acidosis and encephalopathy which may lead to coma and death.

Simultaneously, increased levels of hepatic transaminases (AST, ALT), lactate dehydrogenase and bilirubin are observed together with decreased prothrombin levels that may appear 12 to 48 hours after administration. Clinical symptoms of liver damage are usually evident initially after two days, and reach a maximum after 4 to 6 days.

The Rumack-Matthews nomogram relates plasma levels of paracetamol and the time after oral ingestion to the predicted severity of liver injury. The relation of parenteral paracetamol levels in overdose to liver toxicity has not been examined. Advice or treatment protocols based on oral paracetamol overdoses may not accurately predict the incidence of liver toxicity or need for antidote therapy in Paracetamol solution for infusion overdose.

Methaemoglobinaemia has been reported in cases of paracetamol overdose.

Emergency measures

- Immediate hospitalisation.
- Before beginning treatment, take blood for plasma paracetamol assay, as soon as possible after the overdose.
- Treatment of paracetamol overdose may include the antidote N-acetyl cysteine (NAC) by the IV or oral route. In overdoses of oral paracetamol NAC is administered, if possible, before 8 hours but may give some degree of protection from liver toxicity even after this time. The optimal time for administration of NAC and necessary duration of therapy have not been established for overdoses of Paracetamol solution for infusion.
- Symptomatic treatment.
- Hepatic tests must be carried out at the beginning of treatment and repeated every 24 hours. In most cases hepatic transaminases return to normal in one to two weeks with full restitution of the liver function. In very severe cases, however, liver transplantation may be necessary.

Adults: keep to the recommended dose. Do not take this medicine for longer than a few days at a time unless advised by a doctor.

Children and adolescents: keep to the recommended dose. Do not give this medicine for longer than 48 hours at a time unless advised to by a doctor.

If an **overdose** is taken or suspected, go to a hospital straight away even if you feel well because of the risk of delayed, serious liver damage.

Do not take with other products containing paracetamol, unless advised to do so by a doctor or pharmacist.

For information on the management of overdose, contact the Poison Information Centre on 13 11 26 (in Australia) or 0800 764 766 (in New Zealand).

5 PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

The precise mechanism of the analgesic and antipyretic properties of paracetamol has yet to be established; it may involve central and peripheral actions.

Paracetamol solution for infusion provides onset of pain relief within 5 to 10 minutes after the start of administration. The peak analgesic effect is obtained in 1 hour and the duration of this effect is usually 4 to 6 hours.

Paracetamol 10 mg/mL solution for infusion reduces fever within 30 minutes after the start of administration with a duration of the antipyretic effect of at least 6 hours.

5.2 Pharmacokinetic properties

Absorption

Adults

Paracetamol pharmacokinetics are linear after a single administration of up to 2 g and after repeated administration during 24 hours.

The bioavailability of paracetamol following infusion of 1 g of paracetamol 10 mg/mL is similar to that observed following infusion of 2 g propacetamol (containing 1 g paracetamol). For both these products, peak plasma concentration is obtained as and from the end of infusion. The maximum plasma concentration (C_{max}) of paracetamol observed following intravenous infusion of 1 g paracetamol 10 mg/mL is about 30 µg/mL. About 15 minutes is required to obtain the maximal plasma concentration (T_{max}).

The bioavailability of paracetamol following infusion of 500 mg of paracetamol 10 mg/mL solution is similar to that observed following infusion of 1 g propacetamol (containing 500 mg paracetamol). The maximum plasma concentration (C_{max}) of paracetamol observed at the end of 15-minutes intravenous infusion of 500 mg of paracetamol 10 mg/mL, is about 15 µg/mL.

The pharmacokinetics of oral paracetamol (500 mg) and intravenous propacetamol (1 g) were compared in a randomised, double-blind, 2-period crossover study in 12 healthy male subjects. As expected, plasma concentrations of intravenous propacetamol were significantly higher and obtained earlier, compared to oral administration, however after the first hour and up to 24 hours the plasma concentrations remained similar. (Fig. 1 & Table 1 below)

Figure 1:




Table 1:**Pharmacokinetic parameters of paracetamol (mean \pm sd)**

	Propacetamol 1g IV (n =12)	Paracetamol 500mg oral (n=12)	p value
Cmax ($\mu\text{g/mL}$)	12.72 \pm 3.51	5.49 \pm 1.89	p <0.0001
Tmax (h)	0.25	1.46 \pm 0.57	p <0.0001
t_{1/2} (h)	3.60 \pm 1.07	3.17 \pm 0.41	NS
AUC_{0-12h}	24.07 \pm 3.77	19.48 \pm 3.69	p <0.0001
AUC_{0-∞}	25.5 \pm 4.27	21.04 \pm 4.49	p <0.0001
Cl (L/h/kg)	0.28 \pm 0.04	-	-
Vd (L/kg)	1.29 \pm 0.37	-	-
F	-	82 \pm 9.4	-

F: bioavailability of oral paracetamol (500 mg) versus IV propacetamol (1 g) Cmax: plasma concentration at the end of infusion

Distribution

The volume of distribution of paracetamol is approximately 1 L/kg. Paracetamol is not extensively bound to plasma proteins.

Following infusion of 2 g propacetamol, (equivalent to 1 g of paracetamol) significant concentrations of paracetamol (about 1.5 $\mu\text{g/mL}$) were observed in the cerebrospinal fluid 20 minutes after infusion.

Metabolism

Paracetamol is metabolised mainly in the liver following two major hepatic pathways: glucuronic acid conjugation and sulphuric acid conjugation. The latter route is rapidly saturable at doses that exceed the therapeutic doses. A small fraction (less than 4%) is metabolised by cytochrome P450 to a reactive intermediate (N-acetyl benzoquinone imine) which, under normal conditions of use, is rapidly detoxified by reduced glutathione and eliminated in the urine after conjugation with cysteine and mercapturic acid. However, during massive poisoning, the quantity of this toxic metabolite is increased.

At therapeutic doses, CYP3A4, the major isoform of P450 in human liver, contributes to the production of the cytotoxic metabolite. For very high, supratherapeutic plasma concentrations (1500 mg/ L) of paracetamol, the 2E1 and 1A2 isoforms may also be involved.

Elimination


The metabolites of paracetamol are mainly excreted in the urine. 90% of the dose administered is excreted in 24 hours, mainly as glucuronide (60-80%) and sulphate (20- 30%) conjugates. Less than 5% is eliminated unchanged. Plasma half-life is 2.7 hours and total body clearance is 18 L/h.

Pharmacokinetics in special populations

Neonates and Infants <6 months of age

Clinical trials examining the pharmacokinetics of paracetamol solution for infusion in neonates and infants <6 months of age are limited. The safety and efficacy of paracetamol solution for infusion in premature neonates has not been established. In a trial of twelve children between 1 and 232 days of age, which included five children less than 10 days of age, the pharmacokinetic results for paracetamol solution for infusion were as follows:

Figure 2:



Paracetamol concentrations (means \pm SD) versus time after a 15-min paracetamol infusion. * $p < 0.05$, ** $p < 0.01$, differences between groups.

Table 2:

Pharmacokinetic parameters of all children and of children aged less than and over 10 days.

	Total	<10 days	>10 days	P
$t_{1/2}$ (h)	2.7 (1.0)	3.5 (0.5)	2.1 (0.9)	<0.05
AUC ($\mu\text{g/L/h}$)	41.3 (25.9)	64.0 (23.7)	25.0 (10.9)	<0.01
CL (L/kg/h)	0.275 (0.2)	0.149 (0.067)	0.365 (0.219)	<0.05
V (L/kg)	0.8 (0.2)	0.7 (0.2)	0.9 (0.1)	NS

Results are expressed as means, with SD in parentheses. $T_{1/2}$ = elimination half life; AUC = area under the curve; CL = total body clearance of drug from the plasma; V = volume of distribution

The infants in the study were aged between 1 and 232 days; mean 88 ± 95 days. In the neonates aged less than 10 days, the gestational age was 37.4 ± 3.9 weeks (32 to 41.3 weeks). The weight of the neonates at the time of the study was 2.578 ± 0.959 kg (1 to 3.8); birth weight was 2.578 ± 1.022 kg (1 to 3.920 kg). The mean administered dose was 15.3 ± 2 mg/kg (13.40 to 20 mg/kg).

In neonates the plasma half-life is longer than in infants i.e. around 3.5 hours. Neonates and infants excrete significantly less glucuronide and more sulphate conjugates than adults. The potential effect of immaturity in metabolic and elimination pathways of paracetamol should be considered when administering paracetamol to neonates and children <6 months of age.

Infants and children >6 months of age

The pharmacokinetic parameters of paracetamol observed in infants and children are similar to those observed in adults, except for the plasma half-life that is slightly shorter (1.5 to 2 hours) than in adults.

Elderly

There was a significant increase in AUC and reduction in clearance of paracetamol and its metabolites in elderly subjects. However, these statistically significant differences were not likely to be clinically relevant during short-term infusions. Hence, no dose adjustment is required in this population.

Renal impairment

Paracetamol should be administered with caution to patients with renal impairment. In cases of severe renal impairment (creatinine clearance ≤ 30 mL/min), the elimination of paracetamol is slightly delayed, the elimination half-life ranging from 2 to 5.3 hours. For the glucuronide and sulphate conjugates, the elimination rate is 3 times slower in subjects with severe renal impairment than in healthy subjects. It is recommended that there be an interval of at least 6 hours between administrations in patients with severe renal impairment (creatinine clearance ≤ 30 mL/min) (see section 4.2 DOSE AND METHOD OF ADMINISTRATION).

Hepatic impairment

Paracetamol should be administered with caution to patients with hepatic impairment (see sections 4.3 CONTRAINDICATIONS and 4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE). Hepatic impairment may decrease the clearance of paracetamol or increase the probability of hepatic toxicity.

5.3 Preclinical safety data

Clinical trials were performed with two different formulations of paracetamol, paracetamol solution for infusion and propacetamol¹ (see footnote). Propacetamol 2 g is equivalent to paracetamol solution for infusion 1 g. Refer to section 4.2 DOSE AND METHOD OF ADMINISTRATION for the correct dosing instructions for Paracetamol Kabi.

Analgesia - Adults

Two phase III studies were conducted to compare the safety and analgesic efficacy of intravenous (IV) paracetamol and propacetamol in 303 adults. Two accepted acute pain models, i.e. orthopaedic surgery pain and oral surgery pain were used to evaluate analgesic efficacy.

All the studies presented were phase III, randomised, double-blind, active- and/or placebo-controlled. The studies were well conducted according to the GCP guidelines with ethics approval. Treatment compliance was good in all the studies.

Efficacy of IV paracetamol for the treatment of postoperative pain following orthopaedic surgery.

One hundred and fifty one patients were included in this study; 49 patients were administered paracetamol solution for infusion 1 g and 52 patients placebo. The groups of patients were comparable with regard to demographic and baseline characteristics. One hundred and thirty

¹¹ Propacetamol is a prodrug form of paracetamol which is formed from esterification of paracetamol, and the carboxylic acid diethylglycine

seven (90.7%) of patients received 4 administrations over 24 hours, 2 (1.3%) patients received 3; 2 (1.3%) patients received 2 and 10 (6.6%) patients received only 1 administration.

The primary measured efficacy endpoint parameter of the trial was the evaluation of paracetamol solution for infusion 1 g versus placebo after single dose-pain relief scores (PID, PRID, maxPR, maxPID, SPID, TOTPAR, time to peak effects and time to first rescue medication, numbers and proportion of patients requiring rescue medication (PCA-morphine) and patients global evaluation (PGA)). The secondary measured efficacy endpoint parameter was paracetamol solution for infusion 1 g versus placebo after repeated doses.

An overview of the results are shown in Tables 3a and b

Table 3a:

Overview of analgesic efficacy criteria – single dose evaluation – ITT population

	Inj. APAP (n = 50)	Pbo (n = 52)	P value APAP/Pbo
TOTPAR			
Mean	6.6	2.2	0.0001
SD	5.9	3.8	
SPID			
Mean	2.3	-0.6	0.0001
SD	3.6	3.5	
SPAID			
Mean	104.7	-27.7	0.0001
SD	112.9	92.4	
SPRID			
Mean	9.0	1.6	0.0001
SD	8.7	6.2	
MAXPR			
Mean	2.0	0.9	0.0001
SD	1.4	1.1	
MAXPID			
Mean	1.0	0.4	0.0001
SD	0.8	0.8	
MAXPAID			

Mean	36.6	11.9	0.0001
SD	23.4	20.0	
MAXPRID			
Mean	3.0	1.3	0.0001
SD	2.1	1.8	
Median time to rescue medication (hr)	3.0	0.8	
[95% CI]*	[1.4;4.0]	[0.6;1.1]	0.0001

*CI = confidence interval; Inj. APAP – injectable acetaminophen; Pbo - placebo

Table 3b:

Overview of repeated –dose efficacy criteria – ITT population

	Inj APAP 1g	Pbo	p-value APAP/Pbo
Quantity of rescue medication (mg of equivalent morphine dose) over 24hr			
N	48	52	
Mean	38.33	57.41	0.0007
SD	35.14	52.3	
Number of requested administrations of rescue medication over 24h			
N	48	51	
Mean	47.4	89.3	0.0003
SD	39.1	94.5	
Actual number of administrations of rescue medication over 24hr			
N	48	52	
Mean	27.8	42.3	0.0001
SD	20.2	26.0	
MPI (T₀-T₂₄hr)			
N	46	47	
Mean	1.4	1.6	0.0202
SD	0.5	0.6	
MPAI (T₀-T₂₄hr)			
N	46	47	
Mean	31.6	39.6	0.0006
SD	17.0	18.5	

Composite endpoint MPI (T₀-T₂₄hr)			
N	45	47	
Mean	-20.2	33.1	0.0004
SD	94.6	95.4	
Composite endpoint MPAl (T₀-T₂₄hr)			
N	45	47	
Mean	-25.3	37.8	0.0001
SD	91.7	91.4	
Patient's global evaluation adjusted for rescue medication use (at 24hr)			
N	49	52	
Mean	81.6	61.8	0.0019
SD	42.8	37.3	

Efficacy of IV paracetamol for the treatment of postoperative pain following oral (post dental) surgery.

One hundred and fifty two patients were included in this study; 51 patients were administered paracetamol solution for infusion 1 g and 50 patients placebo. The groups of patients were comparable with regard to demographic and baseline characteristics.

The primary measured efficacy endpoint parameter of the trial was the evaluation of paracetamol solution for infusion 1 g versus placebo after single dose-pain relief scores (PID, PRID, maxPR, maxPID, SPID, TOTPAR, time to peak effects and time to first rescue medication, numbers and proportion of patients requiring rescue medication (PCA-morphine), patients global evaluation (PGA)). The secondary measured efficacy endpoint parameter was paracetamol solution for infusion 1 g versus placebo after repeated doses.

An overview of the results are shown in Table 4.

Table 4:

	Inj. APAP 1 g n=51	Pbo n=50	P value APAP/Pbo
TOTPAR			
Mean	6.9	1.7	0.0001
SD	5.9	3.4	
SPID			
Mean	2.2	-0.4	0.0001
SD	3.1	2.9	

SPAID			
Mean	88.1	-12.4	0.0001
SD	109.3	86.0	
SPRID			
Mean	9.1	1.4	0.0001
SD	8.6	5.5	
MAXPR			
Mean	2.3	1.0	0.0001
SD	1.0	1.2	
MAXPID			
Mean	1.1	0.3	0.0001
SD	0.5	0.6	
MAXPAID			
Mean	32.9	11.0	0.0001
SD	15.6	16.4	
MAXPRID			
Mean	3.4	1.3	0.0001
SD	1.4	1.7	
t-MAXPR			
Median	0.25	0.25	0.5557
[95% CI]	NE**	NE	
t-MAXPID			
Median	0.25	0.25	0.7167
[95% CI]	NE	NE	
t-MAXPAID			
Median	0.5	0.25	0.283
[95% CI]	[0.25;0.5]	NE	
t-MAXPRID			
Median	0.25	0.25	0.5557
[95% CI]	NE	NE	
Median time to onset (min)	8.0	NE	

[95% CI]	[5.0;12.0]	NE	0.0001
Median time to rescue medication (hr)	2.1	0.7	0.0001
[95% CI]*	[1.4;3.4]	[0.5;0.8]	

*CI: confidence interval; **NE: not estimable; Inj APAP: injectable acetaminophen; Pbo: placebo

Analgesia - Children

Efficacy of IV paracetamol with postoperative pain (hernia repair)

One hundred and eighty three patients were included in this study, of which 95 patients were administered paracetamol 15 mg/kg solution for infusion. The groups of patients were comparable with regard to demographic and baseline characteristics.

The primary measured efficacy endpoint parameter of the trial was the evaluation of pain intensity difference (PID) on VAS (investigator rated) at 15, 30 minutes, 1, 2, 3, 4, 5 and 6 hours post-dose. The secondary measured efficacy endpoint parameter for the trial was PID on the objective pain scale (OPS), pain relief rated by the investigator, SPID- OPS, SPID-VAS, TOTPAR, number of children with VAS score \leq 15mm, investigators global evaluation, time to remedication and changes from baseline in HR, SBP and DBP.

An overview of results is shown in Tables 5 and 6.

Table 5:

Mean Scores of Pain Intensity Differences (PID) – VAS (Investigator) – ITT population								
Treatment	T15 min	T30 min	T1h	T2h	T3h	T4h	T5h	T6h
Patient Number	95	95	95	95	95	95	95	95
Inj. Paracetamol	25.6	38.1	38.8	40.4	41.3	40.3	41.0	40.9
SD	20	22.1	22.8	22.9	23.7	24.0	23.9	24.1
P value (b)	0.7944	0.5373	0.1990	0.6196	0.624	0.8397	0.5125	0.5569

(b) PID=BLPI + centre + TRT; BLPI: Baseline Pain Intensity (VAS-investigator); TRT: treatment

Mean Scores of Pain Intensity Differences (PID) – VAS (Child) – ITT population								
Treatment	T15 min	T30 min	T1h	T2h	T3h	T4h	T5h	T6h
Patient Number	45	45	45	45	45	45	45	45
Inj. Paracetamol	20.8	31.7	34.4	36.4	38.8	39.1	39.1	39.6
SD	27.9	29.2	26	25.5	28.7	28.6	28.7	28.6
P value (b)	0.4327	0.9125	0.9275	0.6239	0.9265	0.8965	0.9194	0.6182

(b) PID=BLPI + centre + TRT; BLPI: Baseline Pain Intensity (VAS-child); TRT: treatment

Mean Scores of Pain Intensity Differences- OPS – ITT population								
Treatment	T15 min	T30 min	T1h	T2h	T3h	T4h	T5h	T6h
Patient Number	95	95	95	95	95	95	95	95
Inj. Paracetamol	2.3	3.5	3.7	3.7	4.0	3.9	3.9	4.0
SD	2.8	2.9	3.2	3.0	3.1	3.1	3.1	3.1
P value (b)	0.9218	0.9488	0.4667	0.6266	0.2553	0.2548	0.1900	0.1307

b) PID=BLPI + centre + TRT; BLPI: Baseline Pain Intensity (OPS); TRT: treatment

Mean Scores of Pain Relief – ITT population								
Treatment	T15 min	T30 min	T1h	T2h	T3h	T4h	T5h	T6h
Patient Number	95	95	95	95	95	95	95	95
Inj. Paracetamol	2.4	3.2	3.2	3.3	3.4	3.3	3.4	3.4
SD	1.3	1.2	1.2	1.2	1.2	1.2	1.2	1.2
P value (b)	0.8181	0.5833	0.5540	0.2613	0.1972	0.3599	0.1834	0.1267

b) PID=BLPI + centre + TRT; BLPI: Baseline Pain Intensity (VAS investigator); TRT: treatment

Table 6:

Measure of analgesic efficacy: AUC over 6 hours (mean score \pm sd). ITT population

		Treatment group n = 95	
	Statistics	Inj. APAP	p value
TOTPAR	Mean	19.7	0.2568*
	SD	6.6	
SPID-OPS	Mean	22.8	0.3223*
	SD	17.5	
SPID-VAS (investigator)	Mean	239.4	0.7582*
	SD	132.6	
SPID-VAS (child)	Mean	223.3	0.7649*
	SD	152.2	

*analysis of covariance

Antipyrexia

Propacetamol is a different formulation than paracetamol solution for infusion which delivers 1 g of paracetamol for every 2 g of propacetamol administered.

Antipyretic efficacy & safety of a single administration of 30 mg/kg of IV propacetamol in children (age 3 to 12 years) with acute fever of infectious origin

Forty one children with acute fever (ear temperature between 38.5°C to 41°C) of infectious origin. The groups of patients were comparable with regard to demographic and baseline characteristics.

The primary measured efficacy endpoint parameter of the trial was to evaluate the antipyretic efficacy of a single intravenous dose of 30 mg/kg of propacetamol (equivalent to 15 mg/kg paracetamol solution for infusion) in comparison with placebo in children with acute fever of infectious origin (changes in body temperature (BT) from 0.5 hours to 6 hours post dose).

The secondary measured efficacy endpoint parameter was the evaluation of the percentage of body temperature reduction from baseline at each evaluation time, weighted sum of changes in body temperature over the T₀-T₄ and T₀-T₆ periods, weighted sum of percentages of body temperature reduction over the T₀-T₄ and T₀-T₆ periods, time to reach body temperature below 38°C over the T₀-T₆ period, number and percentage of children with a BT below 38°C over the T₀-T₆ period, maximum value of changes in body temperature and time to occurrence after T₀, vital signs (respiratory rate, heart rate, arterial blood pressure), changes over time after dosing, investigator's global evaluation, time to re-medication (with calculation of time at which 50% of children require re-medication) over the T₀-T₆ period, number and percentage of children requiring rescue medication over the T₀-T₆ period and safety - vital signs & adverse events.

An overview of the results are shown in Tables 7 and 8

Table 7:

Primary criterion: mean body temperature change from baseline of 6hr							
Treatment	T30 Min	T1h	T2h	T3h	T4h	T5h	T6h
Propacetamol							
Mean	0.4	1.0	1.4	1.6	1.6	1.4	1.2
SD	0.3	0.5	0.6	0.6	0.8	0.9	1.2
N	20	20	19	19	19	18	18
Placebo							
Mean	0.1	0.1	0.1	0.0	0.0	-0.1	-0.1
SD	0.4	0.5	0.6	0.7	0.8	0.9	0.8
N	21	21	20	18	14	11	10
Treatment p-value (b)	0.0009	0.0001	0.0001	0.0001	0.0001	0.0001	0.0002
Treatment* centre p-value (c)	0.8713	0.5719	0.4979	0.5606	0.3843	0.5141	0.9323

(b) Response = BL body temp+centre=trt; (c) Response = BLbodytemp+centre+trt+(trt*centre)+trt*BLbodytemp)

Table 8:

Overview of secondary efficacy criteria			
	Propacetamol (n=20)	Placebo (n=21)	p-value
Time to first medication over 6 hr (hr)(median)	Not est.	5.0	0.0046
Number pts receiving ≥ 1 rescue med. n(%)	2 (10%)	11 (52.4%)	0.004
Time to reach BT $<38^{\circ}\text{C}$ over 6hr (hr) (median)	2.0	Not est.	0.0001
Number pts reaching at least once BT $<38^{\circ}\text{C}$ over 6hr n (%)	18 (90%)	5 (23.8%)	0.001
Max BT-change from baseline over 6hr ($^{\circ}\text{C}$)	2.0 ± 0.7	0.6 ± 0.6	0.0001
Tmax BT-change over 6 hr (hr)(median)	3.0	2.0	0.0316
Weighed sum of BT-changes over 6hr ($^{\circ}\text{C/hr}$)	7.9 ± 3.8	-0.1 ± 3.6	0.0001
Weighed sum of BT-changes over 4hr ($^{\circ}\text{C/hr}$)	5.2 ± 2.0	0.2 ± 2.2	0.0001
Weighed sum of % of BT-reduction over 6hr (%/hr)	390 ± 170	-20 ± 190	0.0001
Weighed sum of % of BT-reduction over 4hr (%/hr)	260 ± 90	0 ± 130	0.0001
BT reduction at T0.5 (%)	20 ± 20	0 ± 20	0.0007
BT reduction at T1 (%)	50 ± 20	0 ± 30	0.0001
BT reduction at T2 (%)	70 ± 30	0 ± 40	0.0001
BT reduction at T3 (%)	80 ± 20	0 ± 40	0.0001
BT reduction at T4 (%)	80 ± 40	0 ± 40	0.0001
BT reduction at T5 (%)	70 ± 40	10 ± 50	0.0001
BT reduction at T6 (%)	60 ± 60	-10 ± 40	0.0003

All values are expressed as the mean \pm SD unless otherwise stated

6 PHARMACEUTICAL PARTICULARS

6.1 List of excipients

- Cysteine
- Mannitol
- Water for injection

6.2 Incompatibilities

This medicine must not be mixed with other medicines except those mentioned in section 4.2.

6.3 Shelf life

24 months.

6.4 Special precautions for storage

Vials: Store below 25°C.

freeflex[®] bags: Store below 25°C.

Do not refrigerate or freeze.

6.5 Nature and contents of container

Paracetamol 10 mg/mL solution for infusion is available in clear glass vials of 50mL or 100mL.

Paracetamol 10mg/mL solution for infusion is available in 50 mL and 100 mL **freeflex**[®] bags. **freeflex**[®] bags consist of a primary bag made of polyolefine, and an overpouch as a secondary protective bag. An oxygen absorber is placed between the inner bag and overpouch. The ports are made of polypropylene.

50 mL vials are available in packs of 10.

100 mL vials are available in packs of 10, 12 and 20.

50 mL **freeflex**[®] bags are available in cartons of 20, 50 and 60 bags. 100 mL **freeflex**[®] bags are available in cartons of 20, 50 and 60 bags.

6.6 Special precautions for disposal and other handling

Any unused medicine or waste material should be disposed of in accordance with local Requirements.

7 MEDICINE SCHEDULE

Australia: Schedule 4 (Prescription Medicine)

New Zealand: Prescription

8 SPONSOR

Fresenius Kabi Australia Pty Limited Level 2, 2 Woodland Way
Mount Kuring-gai NSW 2080 Australia
Telephone: (02) 9391 5555

Fresenius Kabi New Zealand Limited,
c/o GNZCC ,
HSBC Tower, Level 14,
188 Quay Street,
Auckland 1010, New Zealand
Freecall: 0800 144 892

9 DATE OF FIRST APPROVAL

7th Jul 2016

10 DATE OF REVISION OF THE TEXT

16 July 2025

SUMMARY TABLE OF CHANGES

Section	Reason for change
4.4, 4.5, 4.8	Amended to include the risk of high anion gap metabolic acidosis (HAGMA) due to pyroglutamate acidosis, along with Minor Editorial Changes (MEC)